While disruption of CD40-CD40L in patients with homozygous mutations is associated with immunodeficiency, heterozygous carriers are unaffected, indicating that therapeutic inhibition of CD40-CD40L may be well-tolerated (68). This evidence concerns the gene CD40LG and Immunodeficiency.